A global agricultural sciences company that develops and sells insecticides, herbicides, fungicides, and plant health products to farmers through distributors and retailers. Its roots trace to 1883, when inventor John Bean, whose almond orchard was being ruined by scale insects, built a high-pressure spray pump in Los Gatos, California — the start of the Bean Spray Pump Company. That firm's initials later gave the company its name, as FMC once stood for Food Machinery Corporation.
Q2 2026 net loss was $186.6M on $222.3M restructuring charges as revenue fell 17% to $867.1M.
The quarter swung to a $186.6M loss on $222.3M of . fell 17% to $867.1M and held at 39.5% as $136.5M of costs drove the decline from a $66.7M profit a year earlier. The company is cutting debt and restructuring through 2027 while sales keep shrinking.
Key takeaways
Net loss attributable to FMC stockholders was $186.6M versus $66.7M a year earlier, primarily due to $222.3M in restructuring and other charges including $136.5M for .
decreased 17% to $867.1M, with down 22% excluding India and FX, driven by a 10% volume decline and 7% price decline from lower orders and legacy product demand.
percentage rose 0.8 points to 39.5% from 38.7% a year earlier as manufacturing cost favorability offset the price and volume headwinds, though gross margin dollars fell 16% to $342.1M.
Section summaries
Management's Discussion and Analysis
Q2 2026 revenue fell 17% to $867M on lower diamide orders and legacy product demand; net loss of $187M driven by $222M in restructuring charges.
⌄
decreased 17% to $867.1M, with organic revenue down 22% excluding India and FX, driven by a 10% volume decline and 7% price decline.
declined 26% to $152.6M as lower price and volume were partially offset by favorable costs and a 3% .
Liquidity actions included a $1.2B offering, a $200M prepayment from a rimisoxafen licensing deal, and planned debt reduction from pending asset sales and a $400M equity investment.
rose 42.7% sequentially to $3,954.3M and fell 62.5% to $1,661.1M.
What changed
Q2 2026 at 39.5% followed the 32.5% Q1 2026 low flagged to watch; it rose 6.9 points from Q1 as cost favorability took hold rather than falling further.
charges of $222.3M in Q2 compare to $94.5M in Q1 2026 and run toward the $560M–$635M total flagged in the Q1 filing, with $136.5M booked this quarter.
fell 17% to $867.1M versus the Q1 2026 watch item for stabilization at $758.6M; instead it rose 14.3% sequentially but declined on volume and price.
India business sale proceeds against the $450M fair value less costs to sell were not reported received in this filing; the strategic review authorized in FY 2025 remains open.
December 2025 patent expirations and any generic chlorantraniliprole entry were flagged through FY 2025 and Q1 2026; this filing does not report a generic entry but cites competitive pricing pressure on diamides.
What to watch
Q3 2026 and to see if the 39.5% level holds under continued tariff and pricing pressure.
Incremental charges against the $560M–$635M total as the plan runs through 2027.
Receipt of India business sale proceeds against the $450M fair value less costs to sell.
Debt paydown progress from the $1.2B notes, $200M rimisoxafen prepayment, pending asset sales, and $400M equity investment against of $3,954.3M.
dollars fell 16% to $342.1M, but margin percentage remained flat at ~39% as manufacturing cost favorability offset price and volume headwinds.
Net loss attributable to FMC stockholders was $186.6M, compared to of $66.7M a year ago, primarily due to $222.3M in restructuring and other charges, including $136.5M for .
declined 26% to $152.6M, with lower price and volume partially offset by favorable costs and a 3% FX .
Liquidity actions include a $1.2B Senior Secured Notes offering, a $200M prepayment from a rimisoxafen licensing deal, and planned debt reduction from pending asset sales and a $400M equity investment.
Full-year 2026 priorities focus on debt paydown, cost reductions under (targeting $200M annual run-rate savings by end-2027), and managing competitive pricing pressure.
Quantitative and Qualitative Disclosures About Market Risk
The information required by this item is provided in Derivative Financial Instruments and Market Risks, under Item 2 Management’s Discussion and Analysis of Financial Condition and Results of Operations.
⌄
The information required by this item is provided in Derivative Financial Instruments and Market Risks, under Item 2 Management’s Discussion and Analysis of Financial Condition and Results of Operations.
Other matters. For additional discussion of developments in the legal proceedings disclosed in Part I, Item 3 of our 2025 Form 10-K, see Notes 11 and 18 to the consolidated financial statements as well as Note 18 included within the Form 10-Q for the three months ended March 31,…
⌄
Other matters. For additional discussion of developments in the legal proceedings disclosed in Part I, Item 3 of our 2025 Form 10-K, see Notes 11 and 18 to the consolidated financial statements as well as Note 18 included within the Form 10-Q for the three months ended March 31, 2026.
In addition to the other information set forth in this Form 10-Q, you should carefully consider the factors discussed in Part I, Item 1A "Risk Factors" of our 2025 Form 10-K, and the Company’s other filings with the SEC, which are available at www.sec.gov and on the Company’s we…
⌄
In addition to the other information set forth in this Form 10-Q, you should carefully consider the factors discussed in Part I, Item 1A "Risk Factors" of our 2025 Form 10-K, and the Company’s other filings with the SEC, which are available at www.sec.gov and on the Company’s website at www.fmc.com.
Forward-Looking Information
We wish to caution readers not to place undue reliance on any forward-looking statements contained herein, which speak only as of the date made. We specifically decline to undertake any obligation to publicly revise any forward-looking statements that have been made to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events.